Backonja Miroslav, Webster Lynn R, Setnik Beatrice, Bass Almasa, Sommerville Kenneth W, Matschke Kyle, Malhotra Bimal K, Wolfram Gernot
a PRA Health Sciences , Salt Lake City , UT , USA.
b Pfizer Inc , Durham , NC , USA.
Am J Drug Alcohol Abuse. 2016 Sep;42(5):539-549. doi: 10.3109/00952990.2016.1167215. Epub 2016 May 21.
ALO-02, comprising pellets of extended-release oxycodone surrounding sequestered naltrexone, is intended to deter abuse.
Determine the abuse potential of intravenous oxycodone combined with naltrexone, which represents simulated crushed ALO-02 in solution, compared with intravenous oxycodone in nondependent, recreational opioid users.
A randomized, double-blind, placebo-controlled, three-way crossover study with naloxone challenge, drug discrimination, and treatment phases. Intravenous treatments included oxycodone hydrochloride 20 mg, oxycodone hydrochloride 20 mg plus naltrexone hydrochloride 2.4 mg (simulated crushed ALO-02 20 mg/2.4 mg), or placebo (0.9% sodium chloride for injection). Primary end points were peak effects (E) and area under the effects curve within 2 h postdose (AUE) on drug liking and high visual analog scales.
Thirty-three participants were randomized into treatment phase, and 29 completed all treatments. Study validity was confirmed with statistically significant differences in E for drug liking and high (p < 0.0001) between intravenous oxycodone and placebo. Intravenous simulated crushed ALO-02 resulted in significantly lower scores than oxycodone on drug liking (E: 58.2 vs. 92.4; AUE: 104.3 vs. 152.4) and high (E: 17.2 vs. 93.1; AUE: 12.0 vs. 133.6), respectively (p < 0.0001, all comparisons). More participants experienced adverse events after intravenous oxycodone (n = 27 [90%]) versus intravenous simulated crushed ALO-02 (n = 4 [12.5%]) or placebo (n = 2 [6.5%]).
Intravenous administration of simulated crushed ALO-02 resulted in significantly lower abuse potential, as assessed by subjective ratings of drug liking and high, than intravenous oxycodone in nondependent, recreational opioid users. This suggests that injection of ALO-02 may not be as desirable to recreational opioid users compared with oxycodone taken for nonmedical reasons.
ALO-02由包埋有纳曲酮的缓释羟考酮微丸组成,旨在防止药物滥用。
在非依赖型娱乐性阿片类药物使用者中,比较静脉注射羟考酮与纳曲酮(模拟溶液中碾碎的ALO-02)的滥用可能性与静脉注射羟考酮的滥用可能性。
一项采用纳洛酮激发试验、药物辨别试验和治疗阶段的随机、双盲、安慰剂对照、三向交叉研究。静脉注射治疗包括20mg盐酸羟考酮、20mg盐酸羟考酮加2.4mg盐酸纳曲酮(模拟碾碎的20mg/2.4mg ALO-02)或安慰剂(0.9%注射用氯化钠)。主要终点是给药后2小时内药物喜好和欣快感视觉模拟量表上的峰值效应(E)和效应曲线下面积(AUE)。
33名参与者被随机分配到治疗阶段,29名完成了所有治疗。静脉注射羟考酮与安慰剂在药物喜好和欣快感的E值上有统计学显著差异(p<0.0001),证实了研究的有效性。静脉注射模拟碾碎的ALO-02在药物喜好(E:58.2对92.4;AUE:104.3对152.4)和欣快感(E:17.2对93.1;AUE:12.0对133.6)方面的得分分别显著低于羟考酮(p<0.0001,所有比较)。与静脉注射模拟碾碎的ALO-02(n = 4 [12.5%])或安慰剂(n = 2 [6.5%])相比,更多参与者在静脉注射羟考酮后出现不良事件(n = 27 [90%])。
在非依赖型娱乐性阿片类药物使用者中,通过药物喜好和欣快感的主观评分评估,静脉注射模拟碾碎的ALO-02的滥用可能性显著低于静脉注射羟考酮。这表明与出于非医疗原因服用的羟考酮相比,娱乐性阿片类药物使用者可能不太愿意注射ALO-02。